Literature DB >> 29951691

Synthesis of interleukin 1 beta and interleukin 6 in human lymphocytes is stimulated by tributyltin.

Shyretha Brown1, Mariam Boules1, Nafisa Hamza2, Xiaofei Wang1, Margaret Whalen3.   

Abstract

Tributyltin (TBT) is a widespread environmental contaminant that is present in human blood and other tissues. It has been shown to disrupt the immune function of human natural killer (NK) cells and to alter the secretion of a number of pro-inflammatory cytokines from immune cells. Secretion of both interleukin 1β (IL-1β) and interleukin 6 (IL-6) from human lymphocytes can be increased dependent upon the level of TBT exposure. This study shows that the TBT-induced increases in secretion of both cytokines are due to TBT-induced increases in the synthesis of these proteins and not simply because of the release of pre-existing cytokine. Furthermore, the data indicate that these TBT-induced increases in IL-1β and IL-6 synthesis require MAP kinase signaling pathways. Additionally, elevated synthesis of IL-1β and IL-6 seen at the highest exposures to TBT (200, 200, 50 nM) were accompanied by increases in the mRNA for these cytokines. TBT-induced increases in IL-1β and IL-6 mRNAs were also shown to be dependent on MAP kinase signaling. The study suggests that TBT has the capacity to increase immune cell production of these 2 important pro-inflammatory cytokines and that this increase is in part explained by increased mRNA for the cytokines.

Entities:  

Keywords:  Interleukin 1 beta; Interleukin 6; MD-PBMCs; Tributyltin

Mesh:

Substances:

Year:  2018        PMID: 29951691      PMCID: PMC6082394          DOI: 10.1007/s00204-018-2248-2

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  48 in total

1.  Interleukin-1beta costimulates interferon-gamma production by human natural killer cells.

Authors:  M A Cooper; T A Fehniger; A Ponnappan; V Mehta; M D Wewers; M A Caligiuri
Journal:  Eur J Immunol       Date:  2001-03       Impact factor: 5.532

2.  Tributyltin alters secretion of interleukin 1 beta from human immune cells.

Authors:  Shyretha Brown; Margaret Whalen
Journal:  J Appl Toxicol       Date:  2014-11-07       Impact factor: 3.446

3.  Expression of interleukin-1beta in human breast carcinoma.

Authors:  L Jin; R Q Yuan; A Fuchs; Y Yao; A Joseph; R Schwall; S J Schnitt; A Guida; H M Hastings; J Andres; G Turkel; P J Polverini; I D Goldberg; E M Rosen
Journal:  Cancer       Date:  1997-08-01       Impact factor: 6.860

Review 4.  Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.

Authors:  Charles A Dinarello
Journal:  Blood       Date:  2011-02-08       Impact factor: 22.113

5.  Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogen-activated protein kinase occurs through modulation of Mnk1-eIF4G interaction.

Authors:  Mayya Shveygert; Constanze Kaiser; Shelton S Bradrick; Matthias Gromeier
Journal:  Mol Cell Biol       Date:  2010-09-07       Impact factor: 4.272

6.  Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis.

Authors:  Niels C Riedemann; Ren-Feng Guo; Travis J Hollmann; Hongwei Gao; Thomas A Neff; Jayne S Reuben; Cecilia L Speyer; J Vidya Sarma; Rick A Wetsel; Firas S Zetoune; Peter A Ward
Journal:  FASEB J       Date:  2003-12-19       Impact factor: 5.191

7.  IL-1alpha gene-transfected human melanoma cells increase tumor-cell adhesion to endothelial cells and their retention in the lung of nude mice.

Authors:  R G Chirivi; C Chiodoni; P Musiani; A Garofalo; S Bernasconi; M P Colombo; R Giavazzi
Journal:  Int J Cancer       Date:  1996-09-17       Impact factor: 7.396

8.  Tributyltin and dibutyltin alter secretion of tumor necrosis factor alpha from human natural killer cells and a mixture of T cells and natural killer cells.

Authors:  Kelsi Hurt; Tasia Hurd-Brown; Margaret Whalen
Journal:  J Appl Toxicol       Date:  2012-10-10       Impact factor: 3.446

9.  Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1beta and NO lead to inactivation of caspases.

Authors:  S Sebens Müerköster; J Lust; A Arlt; R Häsler; M Witt; T Sebens; S Schreiber; U R Fölsch; H Schäfer
Journal:  Oncogene       Date:  2006-02-13       Impact factor: 9.867

Review 10.  Blocking IL-1 in systemic inflammation.

Authors:  Charles A Dinarello
Journal:  J Exp Med       Date:  2005-05-02       Impact factor: 14.307

View more
  5 in total

1.  Exposures to the environmental contaminants pentachlorophenol and dichlorodiphenyltrichloroethane increase production of the proinflammatory cytokine, interleukin-1β, in human immune cells.

Authors:  Tamara J Martin; JaQuel Maise; Sahra Gabure; Margaret M Whalen
Journal:  J Appl Toxicol       Date:  2019-03-25       Impact factor: 3.446

2.  Toll-like receptors in the mechanism of tributyltin-induced production of pro-inflammatory cytokines, IL-1β and IL-6.

Authors:  Aliyah Alcala; Brooke Osborne; Blake Allen; Aleshia Seaton-Terry; Toran Kirkland; Margaret Whalen
Journal:  Toxicology       Date:  2022-04-09       Impact factor: 4.571

3.  The organochlorine pesticides pentachlorophenol and dichlorodiphenyltrichloroethane increase secretion and production of interleukin 6 by human immune cells.

Authors:  Tamara J Martin; Sahra Gabure; JaQuel Maise; Sequena Snipes; Margarita Peete; Margaret M Whalen
Journal:  Environ Toxicol Pharmacol       Date:  2019-09-12       Impact factor: 4.860

4.  Dibutyltin alters immune cell production of the pro-inflammatory cytokines interleukin (IL) 1β and IL-6: role of mitogen-activated protein kinases and changes in mRNA.

Authors:  Linda Sushak; Sahra Gabure; JaQuel Maise; Jessica Arnett; Margaret M Whalen
Journal:  J Appl Toxicol       Date:  2020-03-06       Impact factor: 3.446

Review 5.  Endocrine Disruptor Compounds-A Cause of Impaired Immune Tolerance Driving Inflammatory Disorders of Pregnancy?

Authors:  John E Schjenken; Ella S Green; Tenuis S Overduin; Chui Yan Mah; Darryl L Russell; Sarah A Robertson
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-12       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.